The proposed sale is small and conducted under a pre-arranged 10b5-1 plan, so it carries no negative signal. Monitor the actual sale on Form 4 for completion, but no trading action is warranted based on this filing alone.
Price Chart
Executive Summary
Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to sell 5,550 shares of common stock valued at approximately $624,375, with the sale to be executed through a 10b5-1 plan adopted on May 8, 2026. The filing is a routine advance notice of an intended sale under a pre-arranged trading plan and does not indicate a change in the insider's view of the company's prospects. Given the small size of the proposed sale relative to the company's $6.1B market cap, the filing is neutral and low-impact.
Key Facts
- Officer Simon Read filed a Form 144 to sell 5,550 shares of common stock.
- The estimated aggregate market value of the proposed sale is $624,375.
- The sale is to be made pursuant to a 10b5-1 selling plan dated May 8, 2026.
- The proposed sale represents a very small fraction of the company's $6.1B market capitalization.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 5,550 shares valued at $624,375, representing ~0.01% of market cap.
Risk Factors
- Insider selling could be misinterpreted by the market as a negative signal despite the 10b5-1 plan.
- The actual sale may not occur, but the filing indicates the insider at least considered selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974158-26-000096 |
| Document: 0001974158-26-000096-index.html | 0001974158-26-000096 |
| Document: 0001974158-26-000096.txt | 0001974158-26-000096 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access